<DOC>
	<DOCNO>NCT02761694</DOCNO>
	<brief_summary>An open-label , Phase 1 , dose escalation study ARQ 751 subject advance solid tumor AKT1 , 2 , 3 genetic alteration , activate PI3K mutation PTEN-null .</brief_summary>
	<brief_title>Phase 1 Study ARQ 751 Solid Tumors With AKT1 , 2 , 3 Genetic Alterations , Activating PI3K Mutations PTEN-null</brief_title>
	<detailed_description>This open-label , Phase 1 , dose escalation study ARQ 751 administer orally subject advance solid tumor AKT1 , 2 , 3 genetic alteration , activate PI3K mutation PTEN-null .</detailed_description>
	<criteria>1 . Signed write informed consent grant prior initiation studyspecific procedures 2 . 18 year age old 3 . Histologically cytologically document locally advanced , inoperable metastatic solid tumor document AKT1 , 2 , 3 genetic alteration , activate PI3K mutation PTEN null 4 . Failure respond standard therapy , standard curative therapy exist , tolerable . . Subjects enrol Expanded Cohort 3 prior systemic regimen confirm disease progression . If subject refractory disease progression within 6 month adjuvant treatment , previous treatment consider line treatment rather adjuvant therapy . 5 . Measurable disease 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤ 2 7 . Archival tissue sample and/or fresh tumor biopsy sample : 1 . Subjects agree provide archival and/or fresh tumor biopsy sample 2 . Archival tumor sample collect enrolled subject ; archival tissue sample available , recent core needle biopsy collect 3 . Paired , pre posttreatment , tumor biopsy optional subject enrol Dose Escalation Foodeffect cohorts 4 . Paired tumor biopsy mandatory subject enrol Expanded cohort ; subject agree eligible paired tumor biopsy 8 . Adequate organ function indicate follow laboratory value . All laboratory test must obtain within 7 day prior first dose ARQ 751 : a. Hematological . Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L ii . Platelet count ( Plt ) ≥ 100 x 109/L iii . Hemoglobin ( Hb ) ≥ 9 g/dL iv . International normalized ratio ( INR ) 0.8 upper limit normal ( ULN ) ≤ 3 subject receive anticoagulant therapy Coumadin heparin b. Renal i. Serum creatinine ≤ 1.5 x ULN calculate creatinine clearance ≥ 60 mL/min/1.73 m2 subject serum creatinine level &gt; 1.5 x institutional ULN c. Hepatic . Total bilirubin ≤ 1.5 x ULN ii . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 3 x ULN ≤ 5 x ULN subject know liver metastasis d. Metabolic i. Glycated hemoglobin ( HbA1c ) ≤ 8 % 9 . If subject currently receive bisphosphonates , subject must receive bisphosphonates least four week prior first dose ARQ 751. a. Initiation bisphosphonates study may allow provide subject completes first cycle treatment without dose limit toxicity ( DLT ) Investigator rule tumor progression . 10 . Male female subject childproducing potential must agree use doublebarrier contraceptive measure , oral contraception , avoidance intercourse study 90 day last dose ARQ 751 . 11 . Women childbearing potential must negative serum pregnancy test Screening Period within 48 hour first dose ARQ 751 . `` Women childbearing potential '' define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month prior first dose ARQ 751 . 1 . Anticancer therapy , chemotherapy , immunotherapy , target , hormonal/endocrine therapy , investigational agent within four week prior administration first dose study drug ( two week orally administer drug six week nitrosoureas , mitomycin C , bevacizumab ) 1 . To eligible study treatment , toxicity prior treatment must recover Grade ≤ 1 , except alopecia 2 . Concurrent systemic highdose corticosteroid use intermittently antiemetic regimen , central nervous system ( CNS ) metastases management , part premedication regimen allow 3 . Concurrent standard longterm anticancer hormonal therapy drug include , limited , selective estrogen receptor modulators Gonadotropinreleasing hormone ( GnRH ) analog start least six month first dose ARQ 751 allow 2 . Radiation therapy within four week prior administration first dose ARQ 751 1 . To eligible study treatment , radiation therapyrelated toxicity must recover Grade ≤ 1 prior administration first dose ARQ 751 . 2 . Concurrent palliative radiotherapy local paincontrol may allow provide subject completes first cycle treatment , meet criterion progressive disease , treat lesion include target/nontarget lesion assessment . 3 . Major surgical procedure within four week prior administration first dose ARQ 751 . To eligible study treatment , surgical wound must fully heal surgeryrelated adverse event must recover Grade ≤ 1 . 4 . Previous treatment AKT inhibitor ( e.g. , ARQ 092 , MK2206 , GSK2141795 , AZD5363 ) 5 . Unable unwilling swallow complete daily dose ARQ 751 6 . A corrected QT interval ( QTc ) ≥ 480 msec use Fridericia 's formula ( QTcF ) 7 . History Type 1 2 diabetes mellitus require regular medication ( oral hypoglycemic agent ) fast glucose ≥ 160 mg/dL PreStudy visit 8 . Significant gastrointestinal ( GI ) disorder ( ) could , opinion Investigator , interfere absorption , metabolism , excretion ARQ 751 ( e.g. , Crohn 's disease , ulcerative colitis , extensive gastric resection ) 9 . Known active CNS metastasis and/or carcinomatous meningitis . To eligible study treatment , subject must stable disease ≥ 1 month , confirm magnetic resonance imaging ( MRI ) compute tomography ( CT ) scan , CNS metastases well control lowdose steroid , antiepileptic , symptomrelieving medication . 10 . History myocardial infarction ( MI ) New York Heart Association ( NYHA ) Class IIIV congestive heart failure within 6 month administration first dose ARQ 751 ( MI occur &gt; 6 month first dose ARQ 751 permit ) ; Grade 2 bad conduction defect ( e.g. , right leave bundle branch block ) 11 . Concurrent severe uncontrolled illness related cancer social situation would limit compliance study requirement , include limited : 1 . Psychiatric illness , substance abuse 2 . Ongoing active know infection , include human immunodeficiency virus ( HIV ) infection 12 . Active history malignancy current cancer within 2 year first dose ARQ 751 , exception carcinoma insitu cervix , basal cell carcinoma , superficial bladder tumor curatively treat 13 . Blood transfusion administration growth factor within 5 day prior blood draw use confirm eligibility 14 . Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AKT1</keyword>
	<keyword>AKT2</keyword>
	<keyword>AKT3</keyword>
	<keyword>PI3K</keyword>
	<keyword>PTEN-null</keyword>
	<keyword>solid tumor</keyword>
	<keyword>cancer</keyword>
	<keyword>ARQ 751</keyword>
	<keyword>ArQule</keyword>
</DOC>